Determination of teicoplanin trough concentration target and appropriate total dose during the first 3 days

A retrospective study in patients with MRSA infections

Kazuaki Matsumoto, Naoko Kanazawa, Kazuro Ikawa, Tomohide Fukamizu, Akari Shigemi, Keiko Yaji, Yoshihiro Shimodozono, Norifumi Morikawa, Yasuo Takeda, Katsushi Yamada

Research output: Contribution to journalArticle

29 Citations (Scopus)

Abstract

An initial loading procedure has been recommended to enable teicoplanin to promptly reach an effective serum concentration for the treatment of methicillinresistant Staphylococcus aureus (MRSA). This study aimed to retrospectively evaluate the pharmacokinetics and pharmacodynamics of teicoplanin to determine the therapeutic target for the teicoplanin trough concentration and an appropriate dosing method during the first 3 days. The mean trough concentrations were 13.2 mg/L for patients with eradication of MRSA. Moreover, logistic regression analysis showed that the teicoplanin trough concentration was 13 mg/L to achieve MRSA eradication with a probability of 89.0%. The rates of achieving ≥13 mg/L in ≤24, 24-36 and ≥36 mg/kg (total dose during the first 3 days) groups were 9.1, 48.4 and 87.5%, respectively. These results suggest that the administration of ≥36 mg/kg during the first 3 days is appropriate to promptly obtain a trough concentration target of ≥13 mg/L for the initial treatment of MRSA infections.

Original languageEnglish
Pages (from-to)193-199
Number of pages7
JournalJournal of Infection and Chemotherapy
Volume16
Issue number3
DOIs
Publication statusPublished - 2010 Jun
Externally publishedYes

Fingerprint

Teicoplanin
Staphylococcus aureus
Retrospective Studies
Infection
Therapeutics
Pharmacokinetics
Logistic Models
Regression Analysis
Serum

Keywords

  • Methicillin-resistant Staphylococcus aureus (MRSA)
  • Teicoplanin
  • Therapeutic drug monitoring

ASJC Scopus subject areas

  • Microbiology (medical)
  • Pharmacology (medical)
  • Infectious Diseases

Cite this

Determination of teicoplanin trough concentration target and appropriate total dose during the first 3 days : A retrospective study in patients with MRSA infections. / Matsumoto, Kazuaki; Kanazawa, Naoko; Ikawa, Kazuro; Fukamizu, Tomohide; Shigemi, Akari; Yaji, Keiko; Shimodozono, Yoshihiro; Morikawa, Norifumi; Takeda, Yasuo; Yamada, Katsushi.

In: Journal of Infection and Chemotherapy, Vol. 16, No. 3, 06.2010, p. 193-199.

Research output: Contribution to journalArticle

Matsumoto, Kazuaki ; Kanazawa, Naoko ; Ikawa, Kazuro ; Fukamizu, Tomohide ; Shigemi, Akari ; Yaji, Keiko ; Shimodozono, Yoshihiro ; Morikawa, Norifumi ; Takeda, Yasuo ; Yamada, Katsushi. / Determination of teicoplanin trough concentration target and appropriate total dose during the first 3 days : A retrospective study in patients with MRSA infections. In: Journal of Infection and Chemotherapy. 2010 ; Vol. 16, No. 3. pp. 193-199.
@article{01f062e5295949d4ac7e48de9028ec1f,
title = "Determination of teicoplanin trough concentration target and appropriate total dose during the first 3 days: A retrospective study in patients with MRSA infections",
abstract = "An initial loading procedure has been recommended to enable teicoplanin to promptly reach an effective serum concentration for the treatment of methicillinresistant Staphylococcus aureus (MRSA). This study aimed to retrospectively evaluate the pharmacokinetics and pharmacodynamics of teicoplanin to determine the therapeutic target for the teicoplanin trough concentration and an appropriate dosing method during the first 3 days. The mean trough concentrations were 13.2 mg/L for patients with eradication of MRSA. Moreover, logistic regression analysis showed that the teicoplanin trough concentration was 13 mg/L to achieve MRSA eradication with a probability of 89.0{\%}. The rates of achieving ≥13 mg/L in ≤24, 24-36 and ≥36 mg/kg (total dose during the first 3 days) groups were 9.1, 48.4 and 87.5{\%}, respectively. These results suggest that the administration of ≥36 mg/kg during the first 3 days is appropriate to promptly obtain a trough concentration target of ≥13 mg/L for the initial treatment of MRSA infections.",
keywords = "Methicillin-resistant Staphylococcus aureus (MRSA), Teicoplanin, Therapeutic drug monitoring",
author = "Kazuaki Matsumoto and Naoko Kanazawa and Kazuro Ikawa and Tomohide Fukamizu and Akari Shigemi and Keiko Yaji and Yoshihiro Shimodozono and Norifumi Morikawa and Yasuo Takeda and Katsushi Yamada",
year = "2010",
month = "6",
doi = "10.1007/s10156-010-0038-8",
language = "English",
volume = "16",
pages = "193--199",
journal = "Journal of Infection and Chemotherapy",
issn = "1341-321X",
publisher = "Elsevier BV",
number = "3",

}

TY - JOUR

T1 - Determination of teicoplanin trough concentration target and appropriate total dose during the first 3 days

T2 - A retrospective study in patients with MRSA infections

AU - Matsumoto, Kazuaki

AU - Kanazawa, Naoko

AU - Ikawa, Kazuro

AU - Fukamizu, Tomohide

AU - Shigemi, Akari

AU - Yaji, Keiko

AU - Shimodozono, Yoshihiro

AU - Morikawa, Norifumi

AU - Takeda, Yasuo

AU - Yamada, Katsushi

PY - 2010/6

Y1 - 2010/6

N2 - An initial loading procedure has been recommended to enable teicoplanin to promptly reach an effective serum concentration for the treatment of methicillinresistant Staphylococcus aureus (MRSA). This study aimed to retrospectively evaluate the pharmacokinetics and pharmacodynamics of teicoplanin to determine the therapeutic target for the teicoplanin trough concentration and an appropriate dosing method during the first 3 days. The mean trough concentrations were 13.2 mg/L for patients with eradication of MRSA. Moreover, logistic regression analysis showed that the teicoplanin trough concentration was 13 mg/L to achieve MRSA eradication with a probability of 89.0%. The rates of achieving ≥13 mg/L in ≤24, 24-36 and ≥36 mg/kg (total dose during the first 3 days) groups were 9.1, 48.4 and 87.5%, respectively. These results suggest that the administration of ≥36 mg/kg during the first 3 days is appropriate to promptly obtain a trough concentration target of ≥13 mg/L for the initial treatment of MRSA infections.

AB - An initial loading procedure has been recommended to enable teicoplanin to promptly reach an effective serum concentration for the treatment of methicillinresistant Staphylococcus aureus (MRSA). This study aimed to retrospectively evaluate the pharmacokinetics and pharmacodynamics of teicoplanin to determine the therapeutic target for the teicoplanin trough concentration and an appropriate dosing method during the first 3 days. The mean trough concentrations were 13.2 mg/L for patients with eradication of MRSA. Moreover, logistic regression analysis showed that the teicoplanin trough concentration was 13 mg/L to achieve MRSA eradication with a probability of 89.0%. The rates of achieving ≥13 mg/L in ≤24, 24-36 and ≥36 mg/kg (total dose during the first 3 days) groups were 9.1, 48.4 and 87.5%, respectively. These results suggest that the administration of ≥36 mg/kg during the first 3 days is appropriate to promptly obtain a trough concentration target of ≥13 mg/L for the initial treatment of MRSA infections.

KW - Methicillin-resistant Staphylococcus aureus (MRSA)

KW - Teicoplanin

KW - Therapeutic drug monitoring

UR - http://www.scopus.com/inward/record.url?scp=77955708826&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77955708826&partnerID=8YFLogxK

U2 - 10.1007/s10156-010-0038-8

DO - 10.1007/s10156-010-0038-8

M3 - Article

VL - 16

SP - 193

EP - 199

JO - Journal of Infection and Chemotherapy

JF - Journal of Infection and Chemotherapy

SN - 1341-321X

IS - 3

ER -